Krsnaa Diagnostics (KRSNAA.NS)

What Moves the Stock

1. 01New PPP contract wins with state governments - each major tender (e.g., Maharashtra, Karnataka expansions) can add 200-400 centers and ₹500M-1B in annual revenue
2. 02Same-center scan volume growth - utilization rates at existing facilities (currently estimated 40-50% of capacity) drive margin expansion without incremental capex
3. 03Government healthcare budget allocations - state-level Ayushman Bharat funding and diagnostic reimbursement rate increases directly impact revenue visibility
4. 04Capex deployment pace - ₹1.3B annual capex for new center rollouts signals growth trajectory but creates negative FCF during expansion phases
5. 05Contract renewal rates - PPP contracts expiring in 2026-2028 need renewal at favorable economics to maintain revenue base
6. 06PPP diagnostic centers (estimated 70-75% of revenue) - fixed per-scan rates under government contracts with state health departments
7. 07Private hospital partnerships (estimated 20-25%) - revenue-sharing or fee-per-test arrangements with corporate hospitals
8. 08Direct B2C diagnostic services (estimated 5%) - walk-in patients at company-owned centers

KRSNAA.NS Chart

My Notes

• growth - Company is in rapid expansion phase (15.7% revenue growth, 200+ annual center additions) with negative FCF as it invests for scale.
• Rising rates have moderate negative impact through two channels: (1) Higher borrowing costs for capex financing - company has ₹1.3B annual…
• Watch on earnings: Indian government healthcare expenditure as % of GDP (currently 2.1%, target 2.5% by 2025) - drives PPP tender pipeline, Ayushman Bharat beneficiary enrollment and claims processed - indicates utilization of government health schemes that fund diagnostic reimbursements, State-level fiscal deficit ratios - states with >3% deficits may delay tender releases or extend payment cycles.